AptarGroup (ATR) 44th Annual J.P. Morgan Healthcare Conference summary

Business Overview and Strategic Positioning

• Leading provider in drug delivery, dosing, protection technologies, and consumer product dispensing, with $3.6B in 2024 revenue and a diversified portfolio across pharma, beauty, and closures.

• Pharma is the largest segment, contributing 46% of revenue and 67% of adjusted EBITDA, with a focus on proprietary drug delivery systems and strong IP protection.

• Beauty and Closures segments remain significant, with $1.2B and $700M in 2024 revenue, respectively, and recent revitalization and operational efficiency initiatives.

• No single product or geography drives long-term growth, supporting a highly diversified model.

• Sustainability is a key differentiator, recognized by major publications and integrated across all business lines.

Innovation, Technology, and Sustainability

• Over 7,300 patents granted or pending, with R&D spend at ~3% of sales, primarily focused on pharma innovation.

• Advanced dispensing and dosing solutions maximize user satisfaction and regulatory compliance, with cleanroom standards and high reliability (99.999%).

• New product launches include recyclable nasal spray pumps, preservative-free ophthalmic systems, and digital health platforms.

• Ongoing expansion of technology platforms, including digital and connected devices, AI-assisted quality control, and sustainable solutions.

• The company leverages shared technology platforms and deep regulatory expertise to drive innovation and customer engagement.

Pharma Segment and Pipeline

• Proprietary drug delivery systems account for 72% of pharma sales and are the main growth and profit engine, with strong positions in nasal, inhaler, eye care, dermal, and injectables.

• The pharma pipeline has grown 54% in value and 46% in opportunities since 2019, with a 6+ year average project pipeline.

• Systemic nasal drug delivery is a major innovation, expanding treatment options for neurological and cardiovascular diseases.

• Sustained revenue from long-life-cycle products, with repeat business driving 90% of annual pharma revenue.

• Recent collaborations, such as with Oura and Bausch + Lomb, enhance digital health and patient engagement capabilities.